Lung cancer remains the leading cause of cancer-related deaths globally. In China, nearly half of non-small cell lung cancer (NSCLC) patients carry epidermal growth factor receptor (EGFR) mutations. EGFR tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved the prognosis for patients with EGFR mutations and are considered the preferred treatment for these individuals. Programmed death-ligand 1 (PD-L1) expression levels are now widely used as a biomarker to predict the effectiveness of PD-1/PD-L1 immunotherapy in NSCLC. Additionally, the impact of PD-L1 expression on the efficacy of EGFR-TKIs has garnered considerable attention from researchers. This review explores recent studies on the epidemiology and clinical outcomes associated with PD-L1 in NSCLC patients harboring driver gene mutations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12672-025-02089-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical stage-specific prognostic impact of adequate lymphadenectomy in early-stage lung cancer.
Eur J Cardiothorac Surg
March 2025
Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, ; Taipei City, Taiwan.
Objectives: To assess the prognostic impact of adequate lymphadenectomy and determine the optimal nodal assessment for different clinical stages of lung cancer.
Methods: We retrospectively reviewed 1214 patients with clinical stage I-III non-small cell lung cancer who had preoperative PET/CT and curative surgery (2006-2017). Patients were categorized based on whether they had adequate [R0] or inadequate lymphadenectomy [R(un)].
All segments are created equal: locoregional recurrence and survival after single versus multi-segment resection in patients with clinical stage IA ≤ 2 cm non-small cell lung cancer.
Eur J Cardiothorac Surg
March 2025
Department of Cardiothoracic Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 525 E 68 St, M-404, New York, NY 10065, USA.
Objectives: Compare oncologic outcomes between single-segment and multi-segment resections in patients with clinical stage IA1 and IA2 non-small cell lung cancer.
Methods: A retrospective review (2011-2022) was conducted using a prospectively maintained database. Patients undergoing anatomical segmentectomy for clinical stage IA ≤ 2 cm non-small cell lung cancers were included.
Pilot Study of Metabolomic Biomarkers Associated with Outcomes in Patients with Lung Cancer Undergoing Radiation Therapy.
J Proteome Res
March 2025
Department of Radiation Oncology, The Ohio State University, Columbus, Ohio 43210, United States.
Lung cancer stands as the leading cause of cancer-related death worldwide, impacting both men and women in the United States and beyond. Radiation therapy (RT) serves as a key treatment modality for various lung malignancies. Our study aims to systematically assess the prognosis and influence of RT on metabolic reprogramming in patients diagnosed with nonsmall-cell lung cancer (NSCLC) through longitudinal metabolic profiling.
View Article and Find Full Text PDFLipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair.
Sci Adv
March 2025
Department of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lung cancer exhibits altered metabolism, influencing its response to radiation. To investigate the metabolic regulation of radiation response, we conducted a comprehensive, metabolic-wide CRISPR-Cas9 loss-of-function screen using radiation as selection pressure in human non-small cell lung cancer. Lipoylation emerged as a key metabolic target for radiosensitization, with lipoyltransferase 1 (LIPT1) identified as a top hit.
View Article and Find Full Text PDFActive microgel particle swarms for intrabronchial targeted delivery.
Sci Adv
March 2025
School of Science and Engineering, Chinese University of Hong Kong, Shenzhen, China.
Intrabronchial delivery of therapeutic agents is critical to the treatment of respiratory diseases. Targeted delivery is demanded because of the off-target accumulation of drugs in normal lung tissues caused by inhalation and the limited motion dexterity of clinical bronchoscopes in tortuous bronchial trees. Herein, we developed microrobotic swarms consisting of magnetic hydrogel microparticles to achieve intrabronchial targeted delivery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!